This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment (RIAT)

This study has been completed.
Bristol-Myers Squibb
Information provided by:
Sanofi Identifier:
First received: November 24, 2005
Last updated: November 21, 2007
Last verified: November 2007
To support physicians in their active management of hypertensive patients. By targeting specific systolic and diastolic blood pressure (BP) figures physicians will closely monitor the BP values and as such will have an individualized control of the treatment in each patient.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: An International Registry in Essential Hypertension

Further study details as provided by Sanofi:

Estimated Enrollment: 31870
Study Start Date: March 2004
Study Completion Date: July 2006

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Main criteria are listed hereafter:

Inclusion Criteria:

  • Adult hypertensive
  • Either newly diagnosed and untreated
  • or previously treated and uncontrolled Patients of both sexes with essential hypertension

Exclusion Criteria:

  • Known secondary hypertension
  • Known secondary curable hypertension (i.e. pheochromocytoma, aldosterone producing adenoma, Cushing disease). Patients with renal disease are not excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00258921

Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Pascale BLONDIN, MD Sanofi
  More Information Identifier: NCT00258921     History of Changes
Other Study ID Numbers: R-9511
Study First Received: November 24, 2005
Last Updated: November 21, 2007

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on June 23, 2017